aTYR PHARMA (ATYR) Amortizatization of Intangibles (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Amortizatization of Intangibles came in at $214000.0 in Q2 2026, down 53.28% on a YoY basis from $458000.0 in Q2 2025, and down 16.08% quarter-over-quarter from $255000.0 in Q1 2026.
Powered by 
Analysis
aTYR PHARMA (ATYR) Amortizatization of Intangibles (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has reported Amortizatization of Intangibles for 13 consecutive years, with $214000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Amortizatization of Intangibles fell 53.28% year-over-year to $214000.0; the trailing twelve-month figure through Jun 2026 stood at $1.3 million (down 37.29% YoY), and the FY2025 full-year result was $1.9 million, down 31.46% from the prior year.
- Amortizatization of Intangibles fell to $214000.0 in Q2 2026 per ATYR's latest filing, from $255000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $977000.0 in Q3 2023 and bottomed at -$237000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $536777.8 across 5 years, with a median of $579500.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles sank 234.66% in 2022, then soared 384.81% in 2023.
- Over 5 years, Amortizatization of Intangibles stood at $658000.0 in 2022, then soared by 35.71% to $893000.0 in 2023, then slumped by 38.41% to $550000.0 in 2024, then slumped by 34.36% to $361000.0 in 2025, then slumped by 40.72% to $214000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $214000.0, $255000.0, and $361000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | - |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 1.39 Mn |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | 214,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 214,000.00 |
| Mar 31, 2026 | 255,000.00 |
| Dec 31, 2025 | 361,000.00 |
| Sep 30, 2025 | 512,000.00 |
| Jun 30, 2025 | 458,000.00 |
| Mar 31, 2025 | 523,000.00 |
| Dec 31, 2024 | 550,000.00 |
| Sep 30, 2024 | 609,000.00 |
| Jun 30, 2024 | 735,000.00 |
| Mar 31, 2024 | 811,000.00 |
| Dec 31, 2023 | 893,000.00 |
| Sep 30, 2023 | 977,000.00 |
| Jun 30, 2023 | 626,000.00 |
| Mar 31, 2023 | 675,000.00 |
| Dec 31, 2022 | 658,000.00 |
| Sep 30, 2022 | 365,000.00 |
| Jun 30, 2022 | 677,000.00 |
| Mar 31, 2022 | -237,000.00 |
| Dec 31, 2021 | 212,000.00 |
| Sep 30, 2021 | 206,000.00 |